ATRA - Atara Biotherapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

58.98M

Cash

46.24M

Avg Qtr Burn

-46.04M

Short % of Float

16.11%

Insider Ownership

9.13%

Institutional Own.

68.92%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tab-cel (tabelecleucel) Details Viral infection, Epstein-Barr virus, Nasopharyngeal carcinoma, Hematopoietic cell transplantation , Solid organ transplant	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ATA188 Details Epstein-Barr virus, Multiple sclerosis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ATA3219 Details Blood cancer, Non-Hodgkin lymphoma, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ATA3219 Details Systemic lupus erythematosus, Lupus nephritis, Autoimmune disease	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.